BGP-15

• CAT Number: I004506
• CAS Number: 66611-37-8
• Molecular Formula: C14H22N4O2 • 2HCl
• Molecular Weight: 351.3
• Purity: ≥95%
• Target: PARP
• Solubility: DMSO: ≤ 11.33 mg/mL
• Storage: -20°C
• IUPAC Name: N'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride
• InChI: InChI=1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
• InChIKey: ISGGVCWFTPTHIX-UHFFFAOYSA-N
• SMILES: C1CCN(CC1)CC(CON=C(C2=CN=CC=C2)N)O.Cl.Cl

BGP-15 is a nicotinamide oxime derivative with PARP inhibitory activity. BGP-15 has been found to play a protective role after ischemia-reperfusion injury. BGP-15 inhibits cisplatin-induced adenosine diphosphate ribose polymerization in the kidney. At the same time, BGP-15 can restore cisplatin-induced energy metabolism disorders and maintain ATP levels in its protective tissues.

Reference

[1]. Kennedy TL, et al. BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle. Am J Pathol. 2016 Dec;186(12):3246-3260.
[2]. Salah H, et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med. 2016 Aug 3;8(350):350ra103
[3]. Sapra G, et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun. 2014 Dec 9;5:5705.
[4]. Literati-Nagy B, et al. Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies. Metab Syndr Relat Disord. 2014 Mar;12(2):125-31.
[5]. Sarszegi Z, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.